Nxera Pharma Co., Ltd. Logo

Nxera Pharma Co., Ltd.

Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.

4565 | T

Overview

Corporate Details

ISIN(s):
JP3431300007
LEI:
Country:
Japan
Address:
港区赤坂9−7−2
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nxera Pharma Co., Ltd. (formerly Sosei Group) is a technology-driven biopharmaceutical company focused on the discovery and development of specialty medicines. Its mission is to accelerate the creation of life-changing treatments for patients with unmet medical needs, both in Japan and globally. The company leverages its proprietary structure-based drug design (SBDD) platform and drug development capabilities to advance a diverse pipeline of therapeutic programs. Nxera Pharma actively seeks partnerships to pursue breakthrough discoveries and bring innovative medicines to market, with a focus on areas such as neurology and gastroenterology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 09:06
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-08-08 09:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-08-08 08:57
Report Publication Announcement
確認書
Japanese 8.4 KB
2025-08-08 08:55
Interim Report
半期報告書-第36期(2025/01/01-2025/12/31)
Japanese 287.5 KB
2025-04-16 08:57
Registration Form
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:55
Registration Form
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:53
Registration Form
訂正有価証券届出書(参照方式)
Japanese 39.8 KB
2025-04-16 08:51
Remuneration Information
臨時報告書
Japanese 32.4 KB
2025-03-26 08:42
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:41
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:40
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 40.4 KB
2025-03-26 08:38
Regulatory News Service
臨時報告書
Japanese 28.0 KB
2025-03-26 08:37
Regulatory News Service
内部統制報告書-第35期(2024/01/01-2024/12/31)
Japanese 23.8 KB
2025-03-26 08:36
Regulatory News Service
確認書
Japanese 8.6 KB
2025-03-26 08:35
Annual Report
有価証券報告書-第35期(2024/01/01-2024/12/31)
Japanese 1.3 MB

Automate Your Workflow. Get a real-time feed of all Nxera Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nxera Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nxera Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.